Ascenion’s portfolio company Vakzine Projekt Management GmbH (VPM) and Serum Institute of India (SII) have closed a license agreement providing the institute with the rights to develop and market VPM’s innovative vaccine for the prevention of tuberculosis. The candidate was jointly developed by VPM and scientists of the Max Planck Society and the Helmholtz Centre for Infection Research (HZI). It is currently in Phase II trials. Ascenion was instrumental in negotiating and closing the deal. The agreement is a significant milestone in advancing the vaccine towards application. SII not only has the resources and expertise to develop the vaccine to its full potential, but also shares the partners’ goal of making it available to people of all social classes around the world, at a fair price.
Further information:
Press release HZI <link http: www.helmholtz-hzi.de en news_events news view article complete serum_institute_of_india_acquires_rights_to_german_tb_vaccine _blank external-link-new-window>www.helmholtz-hzi.de
More about VPM <link http: www.vakzine-manager.de _blank external-link-new-window>www.vakzine-manager.de
More about SII <link http: www.seruminstitute.com _blank external-link-new-window>www.seruminstitute.com
